This paper reviews comprehensively the most relevant data on single-agent and combination therapies for advanced colorectal cancer with inherited and acquired microsatellite instability (MSI).
Data Sources
We performed a systematic search on PubMed and MEDLINE articles published from inception to December 2022. We have also searched independent websites including U.S. Food and Drug Administration and ClinicalTrials.gov.
Data Summary
Performing microsatellite stability testing, tumor mutational burden (TMB), and germline mutation analysis could identify patients with metastatic colorectal cancer that benefit from immune checkpoint inhibitor (ICI) therapy. Single-agent pembrolizumab has proven superiority over traditional chemotherapy in these patients. The nivolumab–ipilimumab is the only combination ICI therapy approved in this space. Recently, the anti-PD-1 antibody dostarlimab was granted Food and Drug Administration approval in refractory tissue-agnostic advanced solid cancers with deficient mismatch repair (dMMR). ICIs are also being studied in the adjuvant/neoadjuvant setting in colon cancer patients with dMMR. Newer agents are being scrutinized in this space as well. More solid data on biomarkers predicting responses in patients with MSI-high or TMB-H to various therapies are needed. Given its both clinical and financial toxicity, it is imperative to determine the optimal duration of ICI therapy in individual patients.
Conclusions
Overall, the outlook in advanced colorectal cancer patients with MSI appears optimistic as new and efficacious ICI drugs and combinations are being added to the existing therapeutic armamentarium.
SiegelRLMillerKDFuchsHE,et al.Cancer statistics, 2021. CA Cancer J Clin2021; 71: 7–33.
2.
LiGM. Mechanisms and functions of DNA mismatch repair. Cell Res2008; 18: 85–98.
3.
BolandCRThibodeauSNHamiltonSR, et al.A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res1998; 58: 5248–5257.
4.
de la ChapelleAHampelH. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol2010; 28: 3380–3387.
5.
MuellerJGazzoliIBandipalliamP, et al.Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases. Cancer Res2009; 69: 7053–7061.
6.
McCarthyAJCapo-ChichiJMSpenceT, et al.Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation. J Pathol Clin Res2019; 5: 115–129.
7.
BacherJWFlanaganLASmalleyRL, et al.Development of a fluorescent multiplex assay for detection of MSI-high tumors. Dis Markers2004; 20: 237–250.
8.
HalvorsenTBSeimE. Association between invasiveness, inflammatory reaction, desmoplasia and survival in colorectal cancer. J Clin Pathol1989; 42: 162–166.
9.
KoopmanMKortmanGAMekenkampL, et al.Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer2009; 100: 266–273.
10.
BolandCRGoelA. Microsatellite instability in colorectal cancer. Gastroenterology2010; 138: 2073–2087.
11.
SilvaFCValentinMDFerreiraFO, et al.Mismatch repair genes in Lynch syndrome: a review. Sao Paulo Med J2009; 127: 46–51.
12.
LiKLuoHHuangL, et al.Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int2020; 20: 16.
13.
LuYWajapeyeeNTurkerMS,et al.Silencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1. Cell Rep2014; 8: 501–513.
14.
KimJHBaeJMChoNY,et al.Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway. Oncotarget2016; 7: 14095–14111.
15.
SamsteinRMLeeCHShoushtariAN, et al.Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet2019; 51: 202–206.
16.
ChanTAYarchoanMJaffeeE, et al.Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol2019; 30: 44–56.
17.
StricklerJHHanksBAKhasrawM. Tumor mutational burden as a predictor of immunotherapy response: is more always better?Clin Cancer Res2021; 27: 1236–1241.
18.
ChalmersZRConnellyCFFabrizioD, et al.Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med2017; 9: 34. Published 2017 Apr 19.
19.
FabrizioDAGeorgeTJJrDunneRF, et al.Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. J Gastrointest Oncol2018; 9: 610–617.
20.
IñarrairaeguiMMeleroISangroB. Immunotherapy of hepatocellular carcinoma: facts and hopes. Clin Cancer Res2018; 24: 1518–1524.
21.
SalmaninejadAValilouSFShabgahAG, et al.PD-1/PD-L1 pathway: basic biology and role in cancer immunotherapy. J Cell Physiol2019; 234: 16824–16837.
22.
BuchbinderEIDesaiA. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol2016; 39: 98–106.
23.
LeDTUramJNWangH, et al.PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med2015; 372: 2509–2520.
24.
AndréTShiuKKKimTW, et al.Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med2020; 383: 2207–2218.
25.
AndreTShiuK-KKimTW, et al.Final overall survival for the phase III KN177 study: pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) (abstract). J Clin Oncol2021; 39 (suppl 15; abstr 3500).
26.
AndreTAmonkarMNorquistJM, et al.Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol2021; 22: 665.
27.
EngCKimTWBendellJ, et al.Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol2019; 20: 849–861.
28.
KoyamaSAkbayEALiYY, et al.Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun2016; 7: 10501.
29.
NowickiTSHu-LieskovanSRibasA. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J2018; 24: 47–53.
30.
LenzHJVan CutsemELuisa LimonM, et al.First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol2022; 40: 161–170.
31.
OvermanMJMcDermottRLeachJL, et al.Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol2017; 18: 1182–1191.
32.
OvermanMJLonardiSWongKYM, et al.Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol2018; 36: 773–779.
33.
ChenEXJonkerDJLoreeJM, et al.Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian cancer trials group CO.26 study. JAMA Oncol2020; 6: 831–838.
34.
MarabelleAFakihMLopezJ, et al.Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol2020; 21: 1353–1365.
35.
JinZSinicropeFA. Mismatch repair-deficient colorectal cancer: building on checkpoint blockade. J Clin Oncol2022; 40: 2735–2750.
36.
AndreTBertonDCuriglianoG, et al.Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study. J Clin Oncol2021; 39 (suppl; abstr 9).
37.
LipsonEJTawbiHA-HSchadendorfD, et al.Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). J Clin Oncol2021; 39.
